Results 181 to 190 of about 39,064 (303)

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

British Journal of Haematology, Volume 207, Issue 1, Page 15-26, July 2025.
Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley   +1 more source

Biosimilars: Is absence of proof of difference, proof of absence of difference? [PDF]

, 2011
Mario Dicato
openalex   +1 more source

Biosimilars in der Schweiz : Medizin gegen die steigenden Gesundheitskosten? [PDF]

, 2020
Kobler, Irene, Lenzin, Golda, Liberatore, Florian, Pöhlmann, Johannes, Schmidt, Marion, Wieser, Simon   +5 more
core   +1 more source

Biosimilars for Haematologic Malignancies: The Path to Sustainable Care

European Medical Journal Hematology, 2017
The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products.
Paul Cornes, Arnold G. Vulto, Wojciech Jurczak   +2 more
doaj  

Bills target biosimilar drugs

, 2009
Meredith Wadman
openalex   +1 more source

Biosimilarsubstitution wirtschaftlich nicht effizient – Epoetin-alfa-Biosimilar sicher und bewährt [PDF]

, 2011

openalex   +1 more source

Safety of an Intravitreal Bevacizumab Biosimilar (MVASI)

Clinical &Experimental Ophthalmology, Volume 53, Issue 5, Page 523-528, July 2025.
ABSTRACT Background Intravitreal bevacizumab has been used off‐label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020.
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little   +8 more
wiley   +1 more source

Saving money in the European healthcare systems with biosimilars [PDF]

, 2012
Robert Haustein
openalex   +1 more source

What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups—Sharing Canadian perspectives

Diabetes, Obesity and Metabolism, Volume 27, Issue S5, Page 36-44, July 2025.
Abstract Background The rising cost of insulins are significantly impacting health care expenditure, thereby limiting access to treatment for more people affected by diabetes. Fear and misunderstanding of insulin therapy have worsened with the emergence of biosimilar insulins. Biosimilars are not the same as generic medications.
A. Abitbol, L. Chu
wiley   +1 more source

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany

Patient Preference and Adherence, 2017
John Waller,1 Emma Sullivan,1 James Piercy,1 Christopher M Black,2 Sumesh Kachroo2 1Adelphi Real World, Manchester, UK; 2Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA Objectives: We examined ...
Waller J, Sullivan E, Piercy J, Black CM, Kachroo S   +4 more
doaj